STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to understand the current status of the U.S. dermatological therapeutics industry and to assess it in the medium term from 2008 through 2013. We were particularly interested in understanding the future market potential for the current and emerging technologies and products within the dermatological therapeutics industry. This report assesses the available therapeutic procedures for skin, along with the drugs and technologies currently being used for various skin treatments. The role of public agencies, the regulatory environment, and non-governmental stakeholders has also been examined.
REASONS FOR DOING THIS STUDY
Skin disorders have a high active as well as passive morbidity in most human populations across the world. Yet, most dermatology manufacturers and dermatologists rely on cosmetic applications and procedures for survival.
This study is likely to be of interest to individuals and organizations involved in aspects of dermatological therapeutics industry, such as research, manufacturing and even large buyers in the industry. This report will also be of interest to manufacturers and marketers of dermatological therapeutics industry across the world.
SCOPE OF REPORT
This study introduces the readers to most skin disorders, and some common procedures. However, as regards analysis, this study limits itself to prescription and therapeutic drugs for dermatological disorders. Cosmetic and aesthetic procedures, aging disorders, and wound care, which BCC feels are aspects covered in enough detail elsewhere, have not been covered. Further, nail and hair disorders have also not been reviewed.
Some procedures were described so as to provide an understanding of the alternative and complementary modes of treatment and their important role apart from prescription drug treatment in dermatological therapy.
Thus, recent developments in chemical peels, cryotherapy, ultraviolet, and laser therapy have been overviewed. The report discusses various topical and other dermatologic drugs.
Some industry participants and non-commercial dermatological organizations have been mentioned. The report ends with a brief discussion about significant, recent international market developments reported in various publications.
BCC’s methodology for market analysis and forecast projections includes both primary and secondary research sources. Market growth calculations take into account all factors that are likely to spur or inhibit market growth. Revenue figures are not corrected for inflation and are based on values at the manufacturer level.
Data was compiled from various secondary sources such as government, non-government industry stakeholders, technology and market publications, and other public research data sources.
Primary sources were also used extensively to understand technology, regulatory and market trends, apart from ratification of market forecasts.
ABOUT THE AUTHOR
Vanita Khetan is an entrepreneur and a market analyst who has authored several BCC technology market research reports. She holds a bachelor’s degree in chemistry and a postgraduate degree in management. During her career, she has analyzed U.S., European, and Asian markets in various industry verticals including medical devices, wound care, and pharmaceuticals.